Reay Brown, MD
Glaucoma Specialist · Atlanta, GANPI 1275693459
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (35.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Sight Sciences, Inc. accounts for 83.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $12,449 and has fallen 84.0% since, to $1,988 in 2025.
Across 202 payments — averaging $143.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$24K
- Alcon$1K
- AbbVie$923
- Glaukos Corporation$347
- Sun Pharmaceutical Industries Inc.$309
- NEW World Medical,inc.$210
- plus $2K from 16 others
What the payments were for
- Consulting fees$8,79730%
- Travel & lodging$10,15135%
- Food & beverage$10,02235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 86 | $24,280 |
| Alcon | 22 | $1,252 |
| AbbVie(2 entities) | 31 | $923 |
| Glaukos Corporation | 6 | $347 |
| Sun Pharmaceutical Industries Inc. | 10 | $309 |
| NEW World Medical,inc. | 1 | $210 |
| Dompe US, Inc. | 4 | $189 |
| Harrow Eye, LLC | 5 | $185 |
| Shire North American Group Inc | 2 | $166 |
| Novartis | 8 | $161 |
| Biotissue Holdings Inc. | 1 | $144 |
| Bausch & Lomb Americas Inc. | 6 | $134 |
| Rxsight Inc | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Aerie Pharmaceuticals, Inc. | 3 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $67 |
| Thea Pharma Inc. | 1 | $63 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $60 |
| Oyster Point Pharma, Inc. | 3 | $58 |
| Amgen | 2 | $53 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Omeros Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$13,523
- OMNI$8,994
- SION SURGICAL INSTRUMENT$494
- Clareon$295
- XEN GLAUCOMA TREATMENT SYSTEM$216
- Kahook Dual Blade$210
- Clearpath$210
- Ahmed Glaucoma Valve$210
- Streamline$210
- Via360$210
- TearCare SmartLid$159
- TEARCARE(TM) (2.2) SYSTEM KIT$159
- iStent inject W$149
- XIIDRA$147
- Prokera$144
- AmnioGraft$144
- LenSx$142
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- Oxervate$125
- EYLEA$121
How this compares
Too few glaucoma specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $16,830 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $16,609 |
| LumiganBimatoprost | 22 | $14,175 |
| Prednisolone Acetate | 214 | $11,690 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $10,848 |
| Latanoprost | 615 | $9,047 |
| VyzultaLatanoprostene Bunod | 16 | $5,770 |
| Travoprost | 26 | $4,656 |
| Brinzolamide | 16 | $4,595 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,092 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 101 | $3,880 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 179 | $3,832 |
| Timolol Maleate | 345 | $3,827 |
| Pilocarpine Hcl | 49 | $2,939 |
| Brimonidine Tartrate | 53 | $1,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $923 | $47,61571 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $134 | $5,77016 claims |
| AlconSimbrinza | $1,252 | $4,09220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Atlanta
- Arkadiy YadgarovAtlanta$672K
- Elma ChangAtlanta$9K
- Jean ParkAtlanta$4K
- Derrick PauAtlanta$3K
- Matthew FabrizioAtlanta$2K
- Morohunranti Oguntoye-OumaAtlanta$500
- Ronak PatelDecatur$7K
- David KimSavannah$4K
- Niraj NathanBuford$2K
- Edward WashingtonNorcross$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.